Paolo Tarantino: PostMONARCH is out in Journal of Clinical Oncology
A recent paper by Kevin Kalinsky, Director of the Glenn Family Breast Center at Winship, published in Journal of Clinical Oncology, was mentioned by Paolo Tarantino, Research Fellow at Dana-Farber Cancer Institute, on X:
“PostMONARCH out in Journal of Clinical Oncology.
Fulvestrant/Abemaciclib beyond CDK4/6i progression (mostly beyond palbo) slightly improves PFS (6 vs 5.3 mo) over fulvestrant alone. Not the most active 2nd line combination, though well tolerated, and soon more appealing with oral SERDs combination.”
Authors: Kevin Kalinsky, Giampaolo Bianchini, Erika Hamilton, Lillian Smyth, Seth Wander et al.
Dr. Paolo Tarantino, MD, is pursuing an advanced research fellowship at Dana-Farber Cancer Institute and Harvard Medical School, concurrently working towards a PhD in clinical research at the University of Milan.
His research focuses on exploring the HER2 oncoprotein, investigating the emerging HER2-low subgroup of breast tumors, and developing novel antibody-drug conjugates targeting every subtype of breast cancer. With a publication record exceeding 50 papers on breast cancer, he is recognized as a leading expert in the field.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023